Personalis, Inc. entered into a definitive agreement to be acquired by Tempus AI, Inc. for a total enterprise value of $1.5 billion, net of Tempus's existing ownership interest. Shareholders will receive $16.25 per share in a transaction structured as 100% stock, with Tempus having the option to elect payment in cash for up to 50% of the consideration. Personalis reported preliminary Q2 2026 revenue of $22.4 million. Personalis, Inc. is a genomics company specializing in precision oncology and minimal residual disease monitoring.
